Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

AVI BioPharma's Eteplirsen Meets PrimaryEndpoint For Duchenne Muscular Dystrophy

4/2/2012 7:18 AM ET

AVI BioPharma Inc. (AVII: Quote), a developer of RNA-based therapeutics, reported that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy or DMD. Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant increase in novel dystrophin compared to no increase in the placebo group.

In the study, a shorter duration of eteplirsen treatment, 12 weeks, did not show a significant increase in novel dystrophin, despite administration of the drug at a higher dose, the company added. This finding suggests that a longer duration of dosing is required before meaningful levels of dystrophin are produced.

Eteplirsen is AVI's lead drug candidate that is systemically delivered for the treatment of a substantial subgroup of patients with DMD.

Click here to receive FREE breaking news email alerts for Sarepta Therapeutics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Starbucks Corp. said Thursday after the markets closed that its second quarter profit rose 9.4% from last year, helped by higher revenue. The company's quarterly earnings per share came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. The world's largest specialty coffee retailer also raised its full year earnings outlook. Software giant Microsoft Corp. said Thursday after the markets closed that its third quarter profit fell 6.6% from last year, when results were boosted by special upgrade offer revenues. However, the company's quarterly earnings per share came in above analysts' expectations as did its quarterly revenue. Apple Inc. said Wednesday after the markets closed that its second quarter profit rose 7% from last year, as sales surged and margins improved amid strong sales of its iPhones. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave a slightly downbeat revenue forecast for the current quarter.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.